iSonea products recognised at CES
iSonea (ASX:ISN) has revealed that its asthma monitoring technology was selected to receive a digital technology award at the Consumer Electronics Show, held in Las Vegas in early January.
The company has been given a Tech Podcast Network Innovator Pick Award for its AirSonea wheeze monitoring device.
AirSonea launched in Australia in September last year. The product also has CE Mark approval in Europe, and iSonea is aiming for a US launch this year.
The award also recognises iSonea’s AsthmaSense Prime, the smartphone app used to keep tabs on asthma symptoms.
AsthmaSense Prime uses symptoms, triggers, environmental factors and medication usage statistics to inform patients about changing asthma risks.
iSonea last year added cloud capabilities to its AsthmaSense symptom monitoring system and received a Frost & Sullivan Innovation Award for its efforts.
iSonea (ASX:ISN) shares were trading 4.11% higher at $0.38 as of around 1 pm on Thursday.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
